Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Title of Individual [Domain] Title and Position [Domain] Dr. Pepose [Member] Directors [Member] Dr. George Magrath [Member] Chief Executive Officer [Member] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Title of Individual [Axis] Title and Position [Axis] Product and Service [Domain] Product and Service [Axis] Revision of Prior Period [Axis] Revision of Prior Period [Domain] Revision of Prior Period, Reclassification, Adjustment [Member] Revision of Prior Period, Reclassification, Adjustment [Member] Accounts receivable Additional paid-in capital Warrant fair value from warrant liabilities to additional paid in capital Depreciation Share based compensation for services Employee Benefits and Share-Based Compensation Allowance for credit loss RSUs [Member] Consolidated Balance Sheets [Abstract] Basic (in dollars per share) Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition [Line Items] Schedule of Business Acquisitions, by Acquisition [Table] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash paid for interest Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Change in assets and liabilities: Accounts payable Increase (Decrease) in Accounts Payable Commitments and Contingencies Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Common stock, par value $0.0001; 125,000,000 authorized as of December 31, 2025 and 2024; 69,894,507 and 31,574,657 shares issued and outstanding at December 31, 2025 and 2024, respectively. Stock-based Compensation Expense [Abstract] Current [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Components of Income Tax Provision (Benefit) [Abstract] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Number of shares converted (in shares) Conversion of preferred stock (in shares) Federal Current Federal Tax Expense (Benefit) Total current tax provision (benefit) Current Income Tax Expense (Benefit) Total current liabilities Liabilities, Current Current liabilities: State Current State and Local Tax Expense (Benefit) Interest Rate Deferred Compensation Plan [Abstract] Deferred Compensation Arrangements [Abstract] Federal Total deferred tax liabilities Deferred Tax Liabilities, Gross State Subtotal Deferred Tax Assets, Gross Deferral of research and development costs Deferred Tax Asset, In-Process Research and Development Net deferred tax assets Deferred Tax Assets, Net Total deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Deferred tax assets relating to net operating loss carryforwards Federal and state operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract] State net operating loss carryforward Accruals and other Deferred Tax Assets, Other Federal research credit carryforwards Stock-based compensation Organizational costs Deferred Tax Assets, Tax Deferred Expense, Other Valuation allowance Deferred Tax Assets, Valuation Allowance Warrant Liabilities [Member] Derivative [Member] Derivative liability Balance as of end of period Balance as of beginning of period Derivative Liability, Current Warrant liabilities Derivative Liability, Noncurrent Other Derivative Liabilities Derivatives, Embedded Derivatives [Policy Text Block] Warrant liabilities Derivatives, Methods of Accounting, Derivatives Not Designated or Qualifying as Hedges [Policy Text Block] Diluted (in dollars per share) Effective tax rate Effective Income Tax Rate Reconciliation, Percent Reconciliation of Statutory to Effective Income Tax Rate, Percent [Abstract] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Income tax (benefit) provision at federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Other Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent State income tax, net of federal income tax effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Tax credit Stock-based compensation Share-Based Payment Arrangement, Expense Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Correction [Table] Error Correction [Table] Fair value change in warrant and other derivative liabilities Fair value change in warrant and other derivative liabilities Gain (Loss) on Derivative Instruments, Net, Pretax General and administrative General and Administrative Expense General and Administrative [Member] General and Administrative Expense [Member] Acquired In-Process Research and Development Expenses-Process Research and Development Expenses Consolidated Statements of Comprehensive Loss [Abstract] Income Tax Uncertainties [Abstract] Income Taxes Income Tax Disclosure [Text Block] Reserves or related accruals for interest and penalty on income tax expense Reconciliation of Statutory to Effective Income Tax Rate, Amount [Abstract] Income tax (benefit) provision at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Nontaxable or nondeductible items: [Abstract] Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract] Other Stock compensation State income tax, net of federal income tax effect Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Amount Cash paid for income taxes Interest expense Short-term Investments Investment, Policy [Policy Text Block] Letter Agreement [Member] Total liabilities Liabilities Total liabilities, Series A preferred stock, and stockholders' equity Liabilities and Equity Liabilities, Series A preferred stock and stockholders' equity Liabilities and Equity [Abstract] Funding agreement, related party Accreted liability Related Party [Axis] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Financing activities Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Investing activities Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Operating activities Net and comprehensive loss Net loss Net loss Federal net operating loss carryforward Loss from operations Operating Income (Loss) Consulting expenses unpaid Other income, net Deferred Compensation Plan Defined Benefit Plan Disclosure [Line Items] Schedule of Defined Benefit Plans Disclosures [Table] Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) August 2025 Private Placement [Member] August 2025 Private Placement [Member] February 2026 Private Placement [Member] Proceeds from issuance of common stock Proceeds from issuance of common stock Net Proceeds Gross proceeds from the offering and private offering Proceeds from funding agreement, related party Exercise of stock options Proceeds from Stock Options Exercised Property and equipment, net Bad debt expense Related Party [Domain] Agreement made with investments Related Party Transaction [Line Items] Related Party Transactions Schedule of Related Party Transactions, by Related Party [Table] Research and Development Research and Development Expense, Policy [Policy Text Block] Research and development expense Research and development Research and Development Expense (Excluding Acquired in Process Cost) Accumulated deficit Sale of Stock [Domain] Price per share (in dollars per share) Purchase Price Paid Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Series B Preferred Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Forfeited (in shares) Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Issued (in shares) Weighted average grant date fair value of RSUs granted (in dollars per share) Issued (in dollars per share) Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized stock-based compensation cost Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Outstanding, ending balance (in shares) Outstanding, beginning balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, ending balance (in dollars per share) Outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Expected dividend yield Expected stock price volatility Volatility rate Risk free interest rate Award Type [Domain] All Award Types Equity Award [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Short-term investments Short- Term Investments [Member] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Changes in Series A Preferred Stock and Stockholders' Equity [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Issuance expenses Issuance costs attributed to equity instruments Offering expenses Issuance costs Stockholders' equity: Warrants outstanding (in shares) Number outstanding (in shares) Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Sale of Stock [Axis] Subsidiary, Sale of Stock [Line Items] Supplemental disclosure of cash flow information: Total current assets Assets, Current Current assets: Uncertain tax positions Warrant [Member] Diluted (in shares) Basic (in shares) Investors [Member] Common Stock [Member] Total assets Assets Financial Instruments [Domain] Stock-based Compensation Share-Based Payment Arrangement [Text Block] Statement [Table] Antidilutive Securities, Name [Domain] Balance as of end of period Balance as of beginning of period Investments, Fair Value Disclosure Assets [Abstract] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Liabilities [Abstract] Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] Assets Assets [Abstract] Statement [Line Items] Fair Value of Financial Instruments Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Warrant Activity and Outstanding Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Preferred stock, shares authorized (in shares) Temporary Equity, Shares Authorized Preferred stock, shares issued (in shares) Temporary Equity, Shares Issued Balance (in shares) Balance (in shares) Preferred stock, shares outstanding (in shares) Temporary Equity, Shares Outstanding Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Class of Warrant or Right [Line Items] Class of Stock [Domain] March 2025 Private Placement Warrants and Pre-Funded Warrants [Abstract] March 2025 Warrants [Abstract] Warrants Outstanding [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Operating expenses: Total operating expenses Operating Expenses Net Income (Loss) Per Share [Abstract] Earnings Per Share, Basic [Abstract] Antidilutive securities excluded from computation of net (loss) income per share (in shares) Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net loss per share [Abstract] Net loss per share (Note 11): Anti-dilutive Securities Excluded from Computation of Diluted Net (Loss) Income per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Class of Stock [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock, par value (in dollars per share) Common stock reserved for issuance (in shares) Total stockholders' equity Balance Balance Equity, Attributable to Parent Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Deferred Tax Assets [Abstract] Deferred Tax Liabilities [Abstract] Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Provision for income taxes Total tax provision (benefit) Income Tax Expense (Benefit) Preferred stock, par value $0.0001; 10,000,000 and 9,985,854 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024. Derivative Liability [Abstract] Derivative Liability [Abstract] Warrant liabilities Derivative Liability Warrant Liabilities [Member] Equity Components [Axis] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Equity Component [Domain] Stock Option [Member] Stock Options [Member] Forfeited/Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited/Cancelled (in dollars per share) General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. Aggregate offering price Stock Issued During Period, Value, New Issues Fair value of stock issued to affect the acquisition Exercise of stock options Conversion of preferred stock Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. (in shares) Shares sold (in shares) Common stock shares issued under Purchase Agreement (in shares) Stock-based compensation (in shares) Number of shares of the combined organization owned by the company's pre-acquisition Private Opus stockholders (in shares) Shares issued (in shares) Exercise of stock options (in shares) Exercised (in shares) Conversion of preferred stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities License and Collaboration Revenue and Other Funding Agreements Number of Options [Roll Forward] Summary of RSU Activity [Abstract] Warrants [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Vested and exercisable (in dollars per share) Aggregate intrinsic value, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Vested and expected to vest (in shares) Aggregate intrinsic value (in dollars per share) Weighted-average Assumptions Used in Black-Scholes Option-pricing Model [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Abstract] Acquisition of Opus Genetics [Abstract] Business Combination, Description [Abstract] Net loss per share Number of shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Mergers Commitments and contingencies (Note 3 and Note 9) Adjustments to reconcile net loss to net cash used in operating activities: Accounts payable Accounts Payable, Current Total Accrued Liabilities, Current Professional services Payroll Other Other Accrued Liabilities, Current Accrued Expenses [Abstract] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Company Description and Summary of Significant Accounting Policies Loss before income taxes Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Prepaids and other current assets Increase (Decrease) in Temporary Equity [Roll Forward] Preferred stock, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Assets at fair value Liabilities at fair value Segment Information [Abstract] Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract] Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. Temporary Equity, Stock Issued During Period, Value, New Issues Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Recurring Basis [Member] Fair Value, Recurring [Member] Nonrecurring Basis [Member] Fair Value, Nonrecurring [Member] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Cash received in connection with asset acquisition Exercise of warrants Transfers in into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Asset Class [Domain] Fair Value by Liability Class [Domain] Company Description and Summary of Significant Accounting Policies [Abstract] Balance (in shares) Balance (in shares) Shares, Outstanding Mergers [Abstract] Asset Class [Axis] Liability Class [Axis] Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Deferred Tax Assets and Liabilities Components of Income Tax Provision (Benefit) Reconciliation of Statutory to Effective Income Tax Rate Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Fair Value of Net Assets and IPR&D Acquired Commitments and Contingencies [Abstract] Other share issuances Stock Issued During Period, Value, Other Other share issuances (in shares) Stock Issued During Period, Shares, Other Income Taxes [Abstract] Subsequent Events Deferred Compensation Plan [Abstract] Restricted Stock Units Activity Stock Option Plan Activity Weighted-Average Assumptions Used in Black-Scholes Option-pricing Model Stock-based Compensation [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Restricted Stock Units [Member] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Research and Development [Member] Research and Development Expense [Member] Series A Preferred Stock[Abstract] Related Party Transactions [Abstract] Subsequent Events [Abstract] Conversion of Series A preferred stock into common stock Conversion of Stock, Amount Converted Common stock, conversion basis (in shares) Conversion of Stock, Shares Converted Net liabilities assumed in connection with asset acquisition Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Unrealized loss from short-term investments Unrealized loss Unrealized Gain (Loss) on Investments Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Supplemental non-cash investing and financing transactions: Aggregate intrinsic value, outstanding Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Deferred compensation matched by employer, first match Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Employer contribution Defined Contribution Plan, Employer Discretionary Contribution Amount Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred tax assets relating to net operating loss carryforwards [Abstract] Deferred Tax Assets, Net of Valuation Allowance [Abstract] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Common stock market price per share (in dollars per share) Share Price Financial Instrument [Axis] Series A preferred stock, par value $0.0001; no shares and 14,146 shares were designated as of December 31, 2025 and 2024, respectively; no shares and 14,145.374 shares issued and outstanding at December 31, 2025 and 2024, respectively. Balance Balance Temporary Equity, Carrying Amount, Attributable to Parent Weighted Average Exercise Price [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Award Type [Axis] Cash and Cash Equivalent [Table] Cash and Cash Equivalents [Line Items] Subsequent Event [Member] Income Statement Location [Axis] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Percentage of common stock shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accrued expenses and other liabilities Accrued expenses and other liabilities Acquired intangibles Deferred Tax Assets, Goodwill and Intangible Assets Granted stock for services performed (in shares) Weighted average remaining contractual term, vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Weighted average period to recognized stock-based compensation Weighted average remaining contractual term, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Expected life of options (years) Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Lease expiration date Number of operating segments Number of Operating Segments Other comprehensive loss, net of tax Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Short-term Investments [Abstract] Equity Investments [Abstract] Shares issued, price per share (in dollars per share) Shares issued, price per share (in dollars per share) Change in fair value Fair Value Adjustment of Warrants Vesting [Axis] Vesting [Domain] Financial Liabilities Fair Value Disclosure [Abstract] Financial instruments liabilities at fair value Financial Liabilities Fair Value Disclosure Employer matching contribution, first match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Stock options vested (in shares) Stock options forfeited (in shares) Weighted average fair value per share of options vesting (in dollars per share) Weighted average fair value per share of options granted (in dollars per share) Related Party Transaction [Axis] Related Party Transaction [Domain] Vested on March 31, 2023 [Member] Share-Based Payment Arrangement, Tranche One [Member] Exercise price (in dollars per share) Exercise price (in dollars per share) Rent expense Operating Lease, Cost Accounts Receivable and Allowances for Credit Losses [Abstract] Revenue recognized License and collaborations revenue Retirement Plan Name [Axis] Retirement Plan Name [Domain] Facility and Equipment Leases [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Revenue Recognition Exercisable term Expiration period Weighted average remaining contractual life Accounts Receivable and Allowances for Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Contract Assets and Unbilled Receivables [Abstract] Fair Value of Net Assets Acquired [Abstract] Number of shares issued upon conversion (in shares) Number of shares converted (in shares) Pledging Purpose [Axis] Pledging Purpose [Domain] Tax Jurisdiction of Domicile [Extensible Enumeration] Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] Interest expense Non-cash interest Interest Expense, Nonoperating Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Financial Statement Error Correction [Flag] Document Financial Statement Restatement Recovery Analysis [Flag] Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location License and Collaboration Revenue and Other Funding Agreements [Abstract] Contract assets and unbilled receivables are recognized when goods or services are transferred to the customer before the customer pays or before reimbursement for payment is billed or due, excluding any amounts presented as an account receivable, for contractual agreements due within one year or the normal operating cycle, if longer. Contract Assets and Unbilled Receivables, Current Contract assets and unbilled receivables (Note 10) Number of shares repurchases for the payment of employee taxes. Stock Repurchases for Payment of Employee Taxes, Shares Share repurchases for the payment of employee taxes (in shares) Equity impact of the value of new stock issued in connection with registered direct offering during the period. Stock Issued During Period, Value, Registered Direct Offering Issuance of common stock and prefunded warrants in connection with registered direct offering Number of new stock issued in connection with the at-the-market program and purchase agreement during the period. Stock Issued During Period Shares at-the-Market Program and Purchase Agreement Issuance of common stock in connection with the at-the-market program and purchase agreement (in shares) Number of shares issued after exercise of warrants. Stock Issued During Period Shares, Exercise of Warrants Issuance of common stock pursuant to warrants exercises (in shares) Warrants exercised (in shares) Number of new stock issued in connection with registered direct offering during the period. Stock Issued During Period, Shares, Registered Direct Offering Issuance of common stock and prefunded warrants in connection with registered direct offering (in shares) Equity impact of the value of new stock issued in connection with private offering and private placement during the period. Stock Issued During Period Value of Private Offering and Private Placement Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement Value of stock issued as a result of the exercise of stock warrants. Stock Issued During Period, Value, Stock, Exercise of Warrants Exercise of warrants Equity impact of the value of new stock issued in connection with the at-the-market program and purchase agreement during the period. Stock Issued During Period Value at-the-Market Program and Purchase Agreement Issuance of common stock in connection with the at-the-market program and purchase agreement The amount of decrease in temporary equity due to conversion to common stock during the period. Temporary Equity Stock Conversion Value Conversion of preferred stock The number of shares of temporary equity converted to common stock during the period. Temporary Equity Stock Conversion Shares Conversion of preferred stock (in shares) Number of new temporary equity stock issued during the period. Temporary Equity Stock Issued During Period, Shares, New Issues Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. (in shares) Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and . Includes, but is not limited to, legal and accounting fees and direct costs associated with common stock; ATM and Registered Direct Financing. Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing Issuance costs Amount of decrease in additional paid in capital (APIC) resulting from share repurchases for the payment of employee taxes. Adjustments To Additional Paid In Capital Share Repurchases For Payment Of Employee Taxes Share repurchases for the payment of employee taxes Number of new stock issued in connection with private offering and private placement during the period. Stock Issued During Period Shares of Private Offering and Private Placement Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement (in shares) Collaboration and License Agreement [Abstract] Collaboration and License Agreement [Abstract] The maximum amount funded to support the study. Maximum Amount Funded to Support Study Maximum amount of loan Amount funded to support study BioSense license and assignments agreement entered by the entity. BioSense License and Assignments Agreement [Member] BioSense License and Assignments Agreement [Member] "On June 16, 2021, the Company entered into a license agreement (the "Processa License Agreement") with Processa Pharmaceuticals, Inc. ("Processa"), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and commercialize RX-3117 globally, excluding China." Processa License Agreement [Member] Processa License Agreement [Member] Small Business Innovation Research ("SBIR") grant through the Department of Health and Human Services SBIR Grant Agreement [Member] SBIR Grant Agreement [Member] The Funding and License Agreement dated July 22, 2025, among the Company, its wholly owned subsidiary OpusTX, LLC (together, "Opus"), Eyes on the Future, and the RDH12 Fund. RDH12 Agreement [Member] RDH12 Agreement [Member] The amount of milestone payment received upon achieving performance obligation.. Milestone Payments Amount Received Milestone payments received Milestone payments receivable upon the achievement of development, regulatory and commercial goals. Maximum Amount Of Payments Receivable for Development, Regulatory and Commercial Milestones Maximum amount of payments receivable for development, regulatory and commercial milestones Amount of expense associated with the equity purchase agreement during the current accounting period. Financing Costs Financing costs (Note 7) The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including in-process research and development acquired in a business combination consummated during the period. Research and Development Expense Including Acquired in Process Cost Acquired in-process research and development Acquired in-process research and development The entire disclosure for temporary equity. Temporary Equity Disclosure [Text Block] Series A Preferred Stock A defined-contribution retirement account which allows employees to save a portion of their salary in a tax-advantaged manner. The money earned in a 401(k) Plan is not taxed until after the employee retires, at which time their income will typically be lower than during their working years. Retirement Plan, 401K [Member] 401K Plan [Member] Additional percentage employer matches of the employee's deferred percentage contribution matched. Defined Contribution Plan, Additional Employer Matching Contribution Deferred Additional deferred compensation matched by employer Additional percentage employer matches of the employee's percentage contribution matched. Defined Contribution Plan, Additional Employer Matching Contribution Additional employer matching contribution Series A Preferred Stock [Abstract] Series A Preferred Stock [Abstract] Name of the acquiring entity. Opus Genetics, Inc. [Member] Opus Genetics, Inc. [Member] The amount of milestone payment met by the entity which required FDA's approval. Milestone Payment Required Under FDA's Approval Milestone payment requirements attributed to the FDA's approval The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States. Maximum Percentage of Tiered Royalties Receivable Maximum percentage of tiered royalties receivable The number of performance obligations in accordance with the provisions under ASC 606, the Company identified. Number of Performance Obligations Number of distinct performance obligations Non-cancellation period of constraint for Recognizing Research and Development Revenue, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Non-cancellation Period of Constraint for Research and Development Revenue Non-cancellation period of Constraint for Research and Development Revenue Represents sales milestones. Sales Milestones [Member] Sales Milestones [Member] The amount of non-refundable cash payments received during the period under the collaboration agreement. Non-refundable Cash Payment Received Non-refundable cash payment received Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current. Contract Asset, Current Balance as of beginning of period Balance as of end of period This line item represents amounts invoiced that were previously reflected in the Contract Asset account. Contract Asset, Reclassification to Accounts Receivable Related to Costs Billed under License Agreement Reclassification to accounts receivable related to costs billed under the Viatris License Agreement Viatris license and agreement entered by the entity. Viatris License Agreement [Member] Viatris License Agreement [Member] The amount of potential milestone payment received upon achieving performance obligation. First Potential Milestone Payment to be Received First milestone payments received License transfer fee related to terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others. License Transfer Fee [Member] License Transfer Fee [Member] Disclosure of the material terms of the Viatris License Agreement, including development responsibilities, reimbursement of budgeted development costs, cost-sharing above the contractual threshold amount, territorial development rights, and related side letter arrangements for patent dispute expense sharing. Viatris License and Cost Sharing Agreement Viatris license and cost sharing agreement Represents commercial milestones. Commercial Milestones [Member] Type of Arrangement [Abstract] Represents development, regulatory and commercial milestone. Development, Regulatory and Commercial Milestone [Member] Development, Regulatory and Commercial Milestone [Member] The amount of consideration not recognized during the period for the future milestone or milestones. Future Milestone Method, Revenue not Recognized Milestone payments Opus entered into a license agreement (the "MEEI License") with the Massachusetts Eye and Ear Infirmary ("MEEI"), granting an exclusive worldwide license of MEEI patents for use in the NMNAT1 program for all products and processes including the treatment of retinal disease in humans, and a non-exclusive worldwide license to technological information. Massachusetts Eye and Ear Infirmary License Agreement [Member] Massachusetts Eye and Ear Infirmary License Agreement [Member] Iveric entered into an exclusive patent license agreement (as amended, the "BEST1 License") with Penn and the University of Florida Research Foundation ("UF"), which agreement was assigned to Opus under the terms of the Iveric Agreement. Penn and University of Florida BEST1 License Agreement [Member] BEST1 License Agreement [Member] Opus entered into an asset purchase agreement with Iveric (the "Iveric Agreement") pursuant to which the Company acquired certain assets, including the BEST1 License (as defined below), relating to the BEST1 and RHO products. Iveric Asset Purchase Agreement [Member] Iveric Agreement [Member] BEST1 is in development for the treatment of BEST1-associated retinal disease, an IRD that causes vision loss. BEST1 Program [Member] BEST1 Program [Member] Information related first licensed product, regardless of category. First Licensed Product [Member] First Licensed Product [Member] Opus entered into an amended and restated license agreement (the "LCA5/RDH12 Agreement") with the Trustees of the University of Pennsylvania ("Penn") pursuant to which it was granted an exclusive, royalty-bearing license to certain patents and a non-exclusive license to certain information relating to products directed towards treatment or correction of mutation of the LCA5 or RDH12 genes. University of Pennsylvania LCA5/RDH12 License Agreement [Member] LCA5/RDH12 Agreement [Member] Iveric entered into an exclusive patent license agreement (the "RHO License") by and between Penn and UF pursuant to which the Company has exclusive patent rights and non-exclusive knowhow and data rights with regard to products to treat rhodopsin-mediated diseases as a result of the Iveric Agreement. Penn and UF RHO License Agreement [Member] Penn and UF RHO License Agreement [Member] Entity owned or controlled by another entity. Rexahn stockholders [Member] Rexahn [Member] Merger with Rexahn [Abstract] Merger with Rexahn [Abstract] Number of milestones had been accrued during the period. Number of Milestones Accrued Number of milestones accrued Number of payments were due under the CVR Agreement. Payments due under CVR Agreement Payments for CVR Number of potential milestones had been accrued during the period. Number of Potential Milestones Number of potential milestones Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger. Contingent Value Right Entitled Per Each Share Of Common Stock Held Number of contingent value right received per common stock Apexian Sublicense Agreement [Abstract] The entire disclosure for Apexian Sublicense Agreement related to exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. Apexian Sublicense Agreement [Text Block] Apexian Sublicense Agreement Amount of purchase price consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Asset Acquisition, Purchase Price Consideration Transferred Purchase price Price of a single share of a number of saleable stocks paid or offered to be paid in a asset acquisition transaction. Asset Acquisition, Share Price Multiplied by the fair value per share (in dollars per share) The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including in-process research and development acquired in a asset acquisition consummated discount rate during the period. Excludes software research and development, which has a separate concept. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired In-process Research and Development Expenses Discount Rate Discount Rate Amount of liabilities assumed at the asset acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Net liabilities assumed Amount recognized as of the asset acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Net assets and IPR&D acquired Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the asset acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash acquired The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including in-process research and development acquired in a asset acquisition consummated during the period. Excludes software research and development, which has a separate concept. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Acquired In-process Research and Development Expenses IPR&D Subsequent Events, Additional Information [Abstract] Subsequent Events [Abstract] At-the-market is an instruction given to a broker to place a market order to buy or sell securities at the prevailing market bid or ask price during the period. At-The-Market Program [Member] ATM [Member] The amount of gain (loss) recorded upon close of the business acquisition. Asset Acquisition, Gain (Loss) on Acquisition of Business Gain recorded upon close of Opus Acquisition Gain in connection with asset acquisition Tabular disclosure of gain recorded upon close of business acquisition. Gain Recorded Upon Acquisition [Table Text Block] Gain Recorded Upon Close of Acquisition Percentage of underlying intellectual property associated with IRD therapies of private Opus's assets. Percentage of Underlying Intellectual Property Associated with IRD Therapies in Acquisition Percentage of underlying intellectual property associated with IRD therapies This element represents acquisition-related costs incurred to effect a asset acquisition transaction which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Asset Acquisition, Acquisition Related Costs Acquisition cost The number of asset acquired by the entity during the period. Number of Asset Acquired Number of asset acquired Common Stock Issued for Services [Abstract] Common Stock Issued for Services [Abstract] The weighted average grant-date fair value of stock award granted for services during the reporting period as calculated by applying the disclosed option pricing methodology. Share-Based Compensation Arrangement by Share-Based Payment Award, Services, Grants in Period, Weighted Average Grant Date Fair Value Weighted grant date fair value per share of services granted (in dollars per share) Information related to 2020 equity incentive plan. Equity Incentive Plan 2020 [Member] 2020 Equity Incentive Plan [Member] Restricted Stock Units [Abstract] Restricted Stock Units [Abstract] Information related to 2018 equity incentive plan. Equity Incentive Plan 2018 [Member] 2018 Equity Incentive Plan [Member] Former Options [Abstract] General [Abstract] Aggregate number of common shares available for future issuance. Common Stock, Capital Shares Available for Future Issuance Common stock available for future issuance (in shares) Information related to inducement plan Inducement Plan [Member] Inducement Plan [Member] Information related to 2020 Plan Evergreen Provision. Evergreen Provision Plan 2020 [Member] 2020 Plan Evergreen Provision [Member] Sublicense Agreement [Abstract] Sublicense Agreement [Abstract] Represents development and regulatory milestones. Development and Regulatory Milestones [Member] Sublicense agreement with Apexian Pharmaceuticals, Inc. Apexian Sublicense Agreement [Member] Apexian Sublicense Agreement [Member] Stock Options [Abstract] Stock Options [Abstract] Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, vested and expected to vest Increasing aggregate number of common shares reserved for future issuance. Common stock, increase in shares reserved for future issuance Common stock, increase in shares reserved for future issuance (in shares) Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Aggregate Intrinsic Value Aggregate intrinsic value, vested and expected to vest The period of shares reserved under plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Period of Shares Reserved Under Plan Period of shares reserved under plan Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Exercise Price Vested and expected to vest (in dollars per share) Person who terminated as the designation of chief executive officer by the Board. Former Chief Executive Officer [Member] Former Chief Executive Officer [Member] Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Service Time Condition, Number Vested and exercisable (in shares) Aggregate number of common shares reserved for future issuance" given the addition added to reserve due to Evergreen provision. Aggregate Number of Common Stock reserved for future issuance Number of shares added (in shares) The amount warrant financing costs reclassified to financing activities. Warrant Financing Costs Reclassified to Financing Activities Warrant Financing costs The increase (decrease) during the reporting period in contract assets and unbilled receivables arising from the contracting of goods and services and for work performed for which billing has not occurred, net for uncollectible accounts. Increase (Decrease) in Contract Assets and Unbilled Receivables Contract assets and unbilled receivables Unpaid issuance costs related to equity transactions. Unpaid Issuance Costs Change in unpaid issuance costs The value of noncash or part noncash common stock and Series A preferred stock issued in connection with the asset acquisition. Common Stock and Series A Preferred Stock Issued in Connection with Asset Acquisition Common stock and Series A preferred stock issued in connection with the asset acquisition The amount of non-cash share for stock issuance. Non Cash, Share Issuances Non-cash share issuances The cash inflow from issuance of rights to purchase common shares in connection with private offering and private placement. Proceeds from Issuance of Warrants in Connection with Private Offering and Private Placement Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement The cash inflow associated with the amount received from entity's Registered Direct Offering of stocks and warrants to the public. Proceeds from Issuance in Connection with Registered Direct Offering Proceeds from issuance of common stock and pre-funded warrants in connection with the registered direct offering The cash inflow from the additional capital contribution to the entity in connection with private offering and private placement. Proceeds from Issuance of Common Stock and Pre-funded Warrants in Connection with Private Offering and Private Placement Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement Cash outflow for share repurchases for the payment of employee taxes. Share Repurchases for Payment of Employee Taxes Share repurchases for the payment of employee taxes Amount related to reclassification of warrant liabilities to equity upon exercise in noncash investing or financing activities. Reclassification of Warrant Liabilities to Equity Upon Exercise Reclass of warrant liabilities to equity upon exercise Amount of the related state and local income tax effect on operating loss carry forward. State And Local Operating Loss Carryforwards Tax Effect State operating loss carryforwards, tax effect Amount of the related federal income tax effect on operating loss carry forward. Federal Operating Loss Carryforwards, Tax effect Federal operating loss carryforwards, tax effect Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit state and local operating loss carryforwards. Deferred Tax Assets Tax Credit Carryforwards Research, State,and,Local State research credit carryforwards Amount of the federal research credit carryforwards Utilized during the period. Utilized Federal Research Credit Carryforwards Utilized federal research credit carryforwards Tabular disclosure of the reconciliation using contract asset associated with agreement. Schedule of Reconciliation of Contract Asset Associated [Table Text Block] Reconciliation of Contract Asset assets and Unbilled Receivables Liquidity [Abstract] Liquidity [Abstract] Tabular disclosure of investments, warrant liabilities and derivative liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. Schedule of Fair Value Investments, Warrant Liabilities and Derivative Liabilities Measured On Recurring Basis [Table Text Block] Short-Term Investments, Warrant Liabilities and Derivative Liabilities Measured on a Recurring Basis Disclosure of accounting policy for treatment of contract assets and receivables that are billable but have not been billed as of the balance sheet date. Contract Assets and Unbilled Receivables [Policy Text Block] Contract Assets and Unbilled Receivables Disclosure of accounting policy for the liquidity. Liquidity [Policy Text Block] Liquidity Disclosure of accounting policy for other income (expense), net. Other Income (Expense), Net [Policy Text Block] Other Income, net Disclosure of accounting policy for nature of business. Nature of Business [Policy Text Block] Nature of Business and Basis of Presentation Basis of Presentation [Abstract] Basis of Presentation [Abstract] This element represents types of derivative financial instruments, other which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender). Other Derivative Liabilities [Member] Derivative Liability [Member] Other Derivative Liabilities [Member] Concentration of Credit Risk [Abstract] Concentration of Credit Risk [Abstract] The amount of cash equivalents as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. Cash Equivalents not Eligible for FDIC Coverage Cash equivalents not eligible for coverage Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's acquired In-process research and development expenses. Effective Income Tax Rate Reconciliation, Acquired In-Process Research and Development, Percent Acquired IPR&D Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's research and development expense. Effective Income Tax Rate Reconciliation, Research and Development, Percent Research and development Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's asset acquisition expenses. Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent Private Opus acquisition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's asset acquisition expenses. Effective Income Tax Rate Reconciliation, Asset Acquisition, Amount Private Opus acquisition Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to change in fair value of warrant liabilities. Effective Income Tax Rate Reconciliation, Fair Value Change of Warrant Labilities, Amount Nondeductible change in warrant liability fair value Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to change in fair value of warrant liabilities. Effective Income Tax Rate Reconciliation, Fair Value Change of Warrant Labilities, Percent Nondeductible change in warrant liability fair value Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's acquired In-process research and development expenses. Effective Income Tax Rate Reconciliation, Acquired In-Process Research and Development, Amount Acquired IPR&D Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the entity's research and development expense. Effective Income Tax Rate Reconciliation, Research and Development, Amount Research and development The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. Impairment on Investment Impairments on investments Financings [Abstract] The entire disclosure for information about financings. Financings [Text Block] Financings Supplemental Balance Sheet Information [Abstract] Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development service and supplies. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Services and Supplies Current R&D services and supplies Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs. Deferred Tax Assets, Research and Development Research and development credit carryforward Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from transaction costs associated with asset acquisition. Deferred Tax Assets, Transaction Costs Associated with Asset Acquisition Transaction costs in connection with Opus Acquisition The name of a funding agreement with Foundation Fighting Blindness Retinal Degeneration Fund to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase (MERTK) gene (the "MERTK Program"). Foundation Fighting Blindness Retinal Degeneration Fund Agreement [Member] RDF Agreement [Member] The name of binding letter of agreement with FFB and the Jaeb Center for Health Research ("JCHR") to collaborate on natural history studies involving individuals with retinal dystrophies associated with mutations in multiple genes of interest. Binding Letter Agreement 2022 [Member] 2022 Binding Letter Agreement [Member] Member of the board. Board Member [Member] Dr. Jean Bennett's [Member] Person serving as chair person. Cam Gallagher [Member] Cam Gallagher [Member] This member stands for foundation fighting blindness. Foundation Fighting Blindness [Member] Foundation Fighting Blindness [Member] Lead independent director of the Board. Sean Ainsworth [Member] Sean Ainsworth [Member] The name of a binding letter of agreement with FFB and the JCHR on portions of a study involving individuals with retinal dystrophies associated with mutations in the RDH12 or BEST1 genes (the "Study"). Letter Agreement 2025 [Member] 2025 Letter Agreement [Member] Pre-Merger Financing and Waiver Agreements [Abstract] Potential additional installment payment related to the Foundation Fighting Blindness Retinal Degeneration Fund agreement. Payment of Additional Installment to Support Study under Agreement Potential payment of additional installment The number of equal installments for share-based compensation awards to vest. Share Based Compensation Arrangement By Share Based Payment Award Number Of Equal Installments For Awards To Vest Number of equal annual installments for vesting Period of agreement termination after study completion in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period of Agreement Termination after Study Completion Period of agreement termination after study completion The payable amount related to funded to support the study due under the 2022 Binding Letter Agreement. Payments Due Related to Amount Funded to Support Study Payments due related to amount funded to support study The aggregate total of expenses of consulting with an entity. Consulting Expense Consulting expense The amount funded to support the study payable in initial installment at the time of the agreement. Amount Funded to Support Study, Payable in Initial Installment Amount funded to support study payable in initial installment The aggregate amount paid by the entity related to 2022 Binding Letter Agreement upon its termination. Payment of Final Installment upon Termination of Agreement Payment of final installment amount upon termination of agreement Consultation services receivable period from member of the board, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Consultation Services Receivable Period Consultation services receivable period Payment of initial installment amount related to the Foundation Fighting Blindness agreement. Payment of Initial Installment to Support Study under Agreement Payment of initial installment The amount funded to support the study payable in annual installment. Amount Funded to Support Study, Payable in Annual Installment Amount funded to support study payable in annual installment The final installment amount funded to support the study payable upon upon receipt of semi-annual reports. Final Installment Payable upon Receipt of Semi-annual Reports of Study Final installment payable upon receipt of semi-annual reports of study Number of installments to paid monthly for the loan repayment. Debt Instrument, Number of Installments Number of annual installments chairman of the Board Chairman of the Board [Member] Cam Gallagher [Member] A march 2025 private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts. March 2025 Private Placement [Member] March 2025 Private Placement [Member] Retinal Degeneration Fund Agreement [Abstract] Retinal Degeneration Fund Agreement [Abstract] The aggregate percentage of royalty obligation equals to the amounts funded by RDF under the RDF agreement that serves as the cap for total royalty payments owed by the company to RDF. Percentage of Royalty Payment Obligation Percentage of royalty payment obligation The milestone payment amount received upon the achievement of development, regulatory and commercial goals under the agreement. Milestone Payments Received Milestone payments received The amount of milestone payment receivable under the agreement. Milestone Payment Receivable Milestone payment receivable Buyout interest in entity equals to the percentage of disbursed funds, in the event of a change of control of the Company or a sale or exclusive license of the MERTK Program. Buyout Interest Equals Percentage of Disbursed Funds, in Event of Change of Control or Sale or License Buyout interest in entity equals percentage of disbursed funds The maximum amount of nondilutive funding milestone payments under the agreement to support the development of the Mer proto-oncogene tyrosine kinase gene Program. Maximum Amount of Nondilutive Funding Milestone Payments Maximum amount of nondilutive funding milestone payments A march 2025 private placement warrants that allows the warrant holder to purchase a specified number of a company's securities at a initial exercise price. March 2025 Private Placement Warrants [Member] March 2025 Private Placement Warrants [Member] Threshold amount of daily trading volume on each trading day during the measurement period. Threshold of Daily Trading Volume During Measurement Period Daily trading volume during measurement period The fair value change attributed to the derivative liability. Fair Value Change Attributed to derivative Liability Fair value change in the derivative liability Maximum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants. Maximum Percentage of Beneficial Ownership Limitation Maximum percentage of beneficial ownership limitation Number of consecutive trading days in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Consecutive Trading Days Consecutive trading days A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price. Pre-Funded Warrants [Member] Pre-Funded Warrants [Member] Minimum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants. Minimum Percentage of Beneficial Ownership Minimum percentage of beneficial ownership Number of warrants exercised. Class of Warrant or Right Exercised Warrants exercised (in shares) Private placement warrants exercised (in shares) Financing [Abstract] Financings [Abstract] Per share amount received for each share of common stock issued or sold in the stock transaction. Stock Sold, Price Per Share Purchase price per prefunded warrant (in dollars per share) Offering price (in dollars per share) Pre-funded Registered Direct Offering (RDO) warrants. Pre-funded RDO Warrants [Member] Pre-funded RDO Warrants [Member] The November 2025 Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors. November 2025 Registered Direct Offering [Member] 2025 RDO [Member] Registered Direct Offerings [Abstract] Registered Direct Offerings [Abstract] Number of registered direct offering warrants sold at offering price (per unit). Number of RDO Warrants Sold at Offering Price Number of RDO warrants sold at offering price (in shares) A Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors. Registered Direct Offering [Member] Registered Direct Offering [Member] Registered Direct Offering (RDO) warrants. RDO Warrants [Member] Warrants [Member] Number of securities issued for each share of common stock and warrant. Number of Securities to Purchase in Each Share of Common Stock and Warrant Number of securities to purchase in each share of common stock and warrant (in shares) The amount of underwriting discounts, commissions and offering expenses. Underwriting Discounts Commissions and Offering Expenses Underwriting discounts, commissions and offering expenses A march 2025 warrant that allows the warrant holder to purchase a specified number of a company's securities at a initial exercise price. March 2025 Warrants [Member] March 2025 Warrants [Member] March 2025 financing company entered into an underwriting agreement with Craig-Hallum Capital Group, LLC, as the sole underwriter. March 2025 Financings [Member] March 2025 Financings [Member] A private offering in which common stock is offered and sold on a firm commitment basis through one or more underwriters, all pursuant to (i) an effective registration statement under the Securities Act and (ii) an placement agency agreement between the Company and such agent. Private Offering [Member] Private Offering [Member] A public offering in which common stock is offered and sold on a firm commitment basis through one or more underwriters, all pursuant to (i) an effective registration statement under the Securities Act and (ii) an underwriting agreement between the Company and such underwriters. Underwritten Public Offering [Member] Underwritten Public Offering [Member] Threshold weighted average price per share amount of common stock required to trigger the call of the Company's March 2025 Private Placement Warrants. Threshold Weighted Average Price Per Share Threshold weighted average price per common share (in dollars per share) Transaction costs incurred directly with the issuance of derivative warrant liabilities. Transaction Costs Allocated to Warrant Liabilities Transaction costs At-The-Market Program [Abstract] At-The-Market Program [Abstract] The exercise price range of warrant two. Warrant Exercise Price Two [Member] Exercise Price $1.15 [Member] The exercise price range of warrant three. Warrant Exercise Price Three [Member] Exercise Price $6.09 [Member] The exercise price range of warrant one. Warrant Exercise Price One [Member] Exercise Price $0.95 [Member] Number of warrants or rights exercisable during the period. Class of Warrant or Right Exercisable Number exercisable (in shares) This is a cash inflow, proceeds received from Pre-merger Financing, Proceeds from Pre-Merger Financing Total investment A classification of Information by type of warrant or right issued, for example Series A Warrants. Series A Warrants [Member] Series A Warrants [Member] Number of directors of the company. Number of Directors Number of directors Information by securities purchase agreement. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Pre-Merger Financing of Warrants [Abstract] Pre-Merger Financing [Abstract] common stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") for an equity line financing (the "Purchase Agreement"). Purchase Agreement [Member] Lincoln Park [Member] Lincoln Park Purchase Agreement [Abstract] Lincoln Park Purchase Agreement [Abstract] The term of purchase agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of Purchase Agreement Common stock purchase agreement, term The maximum amount that can be sold under the common stock purchase agreement with Lincoln Park Capital Fund, LLC ("Lincoln Park") for an equity line financing (the "Purchase Agreement"). Maximum Amount to be Sold Under Common Stock Purchase Agreement, Amount Maximum amount purchasable under common stock purchase agreement Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Exercise Price Per Warrant [Abstract] Exercise Price Per Warrant [Abstract] The exercise price per warrant at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Issued in Period, Exercise Price Per Warrant Issued (in dollars per share) The exercise price per warrant at exercised date for nonvested equity-based awards issued during the period on other than stock. Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Exercised in Period, Exercise Price Per Warrant Exercised (in dollars per share) Per share or unit exercise price per warrant of nonvested award under share-based payment arrangement. Excludes share and unit options. Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Exercise Price Per Warrant Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) The exercise price per warrant at exercisable date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans. Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Exercisable in Period, Exercise Price Per Warrant Exercisable at end of period (in dollars per share) Exercisable at beginning of period (in dollars per share) The number of share options (or share units) exercised made during the period on other than stock (or unit) option plans. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Exercised (in shares) Exercise price per warrant as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Expired in Period, Exercise Price Per Warrant Expired (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Weighted Average Term [Abstract] Weighted Average Term (Years) [Abstract] Weighted average remaining contractual term for warrants issued in period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Issued in Period, Weighted Average Remaining Contractual Terms Issued The number of exercisable made during the period on other than stock (or unit) option plans. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable In Period Exercisable at end of period (in shares) Exercisable at beginning of period (in shares) The weighted average fair value at exercisable date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable in Period Weighted Average Grant Date Fair Value Exercisable at beginning of period (in dollars per share) Exercisable at end of period (in dollars per share) Weighted average remaining contractual term of warrants for vested portions of equity-based awards excluding options, exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercisable in Period, Weighted Average Remaining Contractual Term Exercisable The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value Exercised (in dollars per share) Fair value of warrants exercised that were classified as a financial liability. Exercising converts the warrants into shares resulting in company dilution. Derivative Liability Exercises, Current Exercises Amount of derivative liability of issuance of warrants and private placement warrants executed during the period. Derivative Liability, Issuance of Warrants and Private Placement Warrants Issuance of March 2025 Warrants and March 2025 Private Placement Warrants